Gilead Sciences Stock Revenue
| 0QYQ Stock | 89.03 0.41 0.46% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 31.4 B | 27 B |
Gilead | Revenue |
Gilead Sciences Company Revenue Analysis
Gilead Sciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Gilead Sciences Revenue | 28.3 B |
Most of Gilead Sciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Gilead
Projected quarterly revenue analysis of Gilead Sciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Gilead Sciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Gilead Sciences' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Gilead Total Revenue
Total Revenue |
|
Based on the latest financial disclosure, Gilead Sciences reported 28.3 B of revenue. This is much higher than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The revenue for all United Kingdom stocks is 199.94% lower than that of the firm.
Gilead Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is currently under evaluation in revenue category among its peers.
Gilead Fundamentals
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 129 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 88.37 % | ||||
| Revenue | 28.3 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 13.95 B | ||||
| Net Income | 5.67 B | ||||
| Book Value Per Share | 14.83 X | ||||
| Cash Flow From Operations | 9.07 B | ||||
| Number Of Employees | 18 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 80.16 B | ||||
| Total Asset | 67.95 B | ||||
| Retained Earnings | 15.69 B | ||||
| Annual Yield | 0.0005 % | ||||
| Net Asset | 67.95 B | ||||
| Last Dividend Paid | 3.06 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.